Uridine Monophosphate
-
Subject Areas on Research
- Crystal structures of Toxoplasma gondii uracil phosphoribosyltransferase reveal the atomic basis of pyrimidine discrimination and prodrug binding.
- Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.
- Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.
- Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans.
- Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
- Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
- Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
- Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
- Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
- Mechanism of OMP decarboxylation in orotidine 5'-monophosphate decarboxylase.
- Membrane translocation and regulation of uridine diphosphate-glucuronic acid uptake in rat liver microsomal vesicles.
- PHOTON-2: hope for patients with HIV and HCV co-infection?
- Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment.
- Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data.
- Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.
- Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.
- Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
- Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.
- Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
- The mechanisms of citrate on regulating the distribution of carbon flux in the biosynthesis of uridine 5'-monophosphate by Saccharomyces cerevisiae.
- The rapid evolution of treatment strategies for hepatitis C.